Publications by authors named "Katrin Herzog Tzarfati"
Article Synopsis
- A phase II clinical study evaluated the effectiveness of a treatment combo (ibrutinib, bendamustine, and rituximab) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after stem cell transplants or in elderly patients.
- The study showed a 49.1% overall response rate among patients who received at least one cycle, with better outcomes for those with relapsed disease (72.3%) versus refractory disease (37.8%).
- Patients experiencing complete or partial responses had significantly longer median overall survival of 28.1 months, while common side effects included fatigue, diarrhea, and nausea, indicating that the treatment is both safe and effective for those needing potential transplantation.
The COVID-19 pandemic continues to pose challenges to the treatment of hemato-oncology patients. Emergence of COVID-19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confirmed COVID-19 during the Omicron outbreak.
View Article and Find Full Text PDFBackground And Objectives: The COVID-19 pandemic has led to a growing interest in hospital-at-home programmes, including home transfusion services. We studied whether the pandemic had influenced patients' perception of home transfusions.
Materials And Methods: We conducted a survey among haematology patients who receive transfusions in the hospital day care facility.
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 313 patients, 36% experienced severe respiratory infections, 61% were hospitalized, and 20% died, with older age and hypertension linked to worse outcomes.
- * Among treatments, only remdesivir significantly reduced mortality, while other therapies like convalescent plasma and corticosteroids showed no clinical benefit.
Patients with hematologic malignancies have an increased risk of severe COVID-19 infection. Vaccination against COVID-19 is especially important in these patients, but whether they develop an immune response following vaccination is unknown. We studied serologic responses to the BNT162b2 vaccine in this population.
View Article and Find Full Text PDFBackground: In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon have been described after receiving vaccinations.
View Article and Find Full Text PDFIntroduction: The myeloproliferative neoplasms (MPN) are clonal diseases that confer an increased risk of thrombohemorrhagic complications. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disease associated with an increased thrombotic risk. Small PNH clones are prevalent in aplastic anemia and myelodysplastic syndrome patients, but their prevalence in MPN patients is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Multiple myeloma is a type of blood cancer and is the second most common kind.
- Researchers used a special technique called single cell RNA sequencing to study how the disease varies in 40 people, including healthy ones, and found that how the disease behaves can be very different from person to person.
- They discovered rare cancer cells in patients who didn’t have symptoms or after treatment, which could help doctors create more personalized treatments for patients with multiple myeloma.
Introduction: Azacitidine (AZA) dose reduction is a common practice in cytopenic patients. However, a correlation between AZA dose and infection complications has never been studied.
Patients And Methods: Higher-risk patients with myelodysplastic syndrome or acute myeloid leukemia treated with AZA in 18 Israeli hospitals between the years 2008 and 2011 were included in a former national survey.
Hypomethylating agents have become the standard therapy for patients with high-risk myelodysplastic syndrome (MDS). In Israel, azacitidine (AZA) is routinely used. Yet, infectious complications are common during AZA therapy.
View Article and Find Full Text PDF